{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,18]],"date-time":"2026-04-18T06:03:42Z","timestamp":1776492222964,"version":"3.51.2"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T00:00:00Z","timestamp":1767657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T00:00:00Z","timestamp":1768435200000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA257679"],"award-info":[{"award-number":["U01CA257679"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U01CA249955 , R01CA186646"],"award-info":[{"award-number":["U01CA249955 , R01CA186646"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA134674"],"award-info":[{"award-number":["R01CA134674"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21CA209533"],"award-info":[{"award-number":["R21CA209533"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DNA damage response genes (DDRG), implicated in several cancers as both predisposing risk factors as well as biomarkers for aggressiveness, have not been fully explored in multiple myeloma (MM).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Herein, we analyzed disease associations of pathogenic variations in nine putative candidate genes using 3 446 MM cases and 323 233 cancer-free controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Increased MM risk was found to be associated with inherited rare pathogenic mutations in\n                      <jats:italic>TP53<\/jats:italic>\n                      ,\n                      <jats:italic>ATM<\/jats:italic>\n                      ,\n                      <jats:italic>CHEK2<\/jats:italic>\n                      ,\n                      <jats:italic>KDM1A<\/jats:italic>\n                      ,\n                      <jats:italic>and ARID1A<\/jats:italic>\n                      , with an enrichment of these variants among individuals with early onset or family history of MM. Individuals with\n                      <jats:italic>TP53<\/jats:italic>\n                      or\n                      <jats:italic>ATM<\/jats:italic>\n                      germline mutations are also likely to have worse overall survival.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our results suggest expansion of the phenotypic spectrum of some of these DDRG to include MM. The identification of these germline predisposition genes opens the avenue for targeted screening of higher risk individuals especially those with young-onset or a family history of plasma cell gammopathies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13045-025-01776-1","type":"journal-article","created":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T16:44:30Z","timestamp":1767717870000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Multiple myeloma risk linked to DNA damage response genes"],"prefix":"10.1186","volume":"19","author":[{"given":"Michael","family":"Conry","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Irina","family":"Ostrovnaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yelena","family":"Kemel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saloni","family":"Sinha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linda B.","family":"Baughn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian","family":"Avery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kylee","family":"Maclachlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria","family":"Groner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lauren","family":"Banaszak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aaron","family":"Norman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicholas J.","family":"Boddicker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alyssa","family":"Clay-Gilmour","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shaji","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ellen","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sita","family":"Dandiker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitul","family":"Waghmare","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susan","family":"Slager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas W.","family":"Sborov","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Judy","family":"Garber","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth E.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle","family":"Hildebrandt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Parameshwaran","family":"Hari","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicola","family":"Camp","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celine","family":"Vachon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saad","family":"Usmani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth","family":"Offit","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vijai","family":"Joseph","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,6]]},"reference":[{"key":"1776_CR1","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1182\/blood-2014-10-567370","volume":"125","author":"J Corre","year":"2015","unstructured":"Corre J, Munshi N, Avet-Loiseau H. Genetics of multiple myeloma: another heterogeneity level? Blood. 2015;125:1870\u20136.","journal-title":"Blood"},{"key":"1776_CR2","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1016\/j.beha.2005.01.006","volume":"18","author":"MJ Higgins","year":"2005","unstructured":"Higgins MJ, Fonseca R. Genetics of multiple myeloma. Best Pract Res Clin Haematol. 2005;18:525\u201336.","journal-title":"Best Pract Res Clin Haematol"},{"key":"1776_CR3","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2019.00424","volume":"10","author":"S Janz","year":"2019","unstructured":"Janz S, Zhan F, Sun F, Cheng Y, Pisano M, Yang Y, et al. Germline risk contribution to genomic instability in multiple myeloma. Front Genet. 2019;10:424.","journal-title":"Front Genet"},{"key":"1776_CR4","doi-asserted-by":"publisher","first-page":"2147","DOI":"10.1002\/ijc.24514","volume":"125","author":"SY Kristinsson","year":"2009","unstructured":"Kristinsson SY, Bjorkholm M, Goldin LR, Blimark C, Mellqvist UH, Wahlin A, Turesson I, Landgren O. Patterns of hematologic malignancies and solid tumors among 37,838 first-degree relatives of 13,896 patients with multiple myeloma in Sweden. Int J Cancer. 2009;125:2147\u201350.","journal-title":"Int J Cancer"},{"key":"1776_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1056\/NEJMoa0708704","volume":"359","author":"HT Lynch","year":"2008","unstructured":"Lynch HT, Ferrara K, Barlogie B, Coleman EA, Lynch JF, Weisenburger D, Sanger W, Watson P, Nipper H, Witt V, Thome S. Familial myeloma. N Engl J Med. 2008;359:152\u20137.","journal-title":"N Engl J Med"},{"key":"1776_CR6","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1001\/jama.2017.11137","volume":"318","author":"D Mandelker","year":"2017","unstructured":"Mandelker D, Zhang L, Kemel Y, Stadler ZK, Joseph V, Zehir A, et al. Mutation detection in patients with advanced cancer by universal sequencing of cancer-related genes in tumor and normal DNA vs guideline-based germline testing. JAMA. 2017;318:825\u201335.","journal-title":"JAMA"},{"key":"1776_CR7","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1038\/s41588-021-00949-1","volume":"53","author":"P Srinivasan","year":"2021","unstructured":"Srinivasan P, Bandlamudi C, Jonsson P, Kemel Y, Chavan SS, Richards AL, Penson AV, Bielski CM, Fong C, Syed A, et al. The context-specific role of germline pathogenicity in tumorigenesis. Nat Genet. 2021;53:1577\u201385.","journal-title":"Nat Genet"},{"key":"1776_CR8","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1038\/s41408-025-01283-z","volume":"15","author":"NJ Boddicker","year":"2025","unstructured":"Boddicker NJ, Mwangi R, Robinson DP, Allmer C, Rosenthal AC, Habermann TM, Feldman AL, Rimsza LM, King RL, Larson MC, et al. Risk of lymphoid malignancy associated with cancer predisposition genes. Blood Cancer J. 2025;15:71.","journal-title":"Blood Cancer J"},{"key":"1776_CR9","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1158\/2643-3230.BCD-23-0208","volume":"5","author":"S Thibaud","year":"2024","unstructured":"Thibaud S, Subaran RL, Newman S, Lagana A, Melnekoff DT, Bodnar S, Ram M, Soens Z, Genthe W, Brander T, et al. Multiple myeloma risk and outcomes are associated with pathogenic germline variants in DNA repair genes. Blood Cancer Discov. 2024;5:428\u201341.","journal-title":"Blood Cancer Discov"},{"key":"1776_CR10","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/bjc.2011.382","volume":"105","author":"M Javle","year":"2011","unstructured":"Javle M, Curtin NJ. The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer. 2011;105:1114\u201322.","journal-title":"Br J Cancer"},{"key":"1776_CR11","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1038\/s41588-021-00885-0","volume":"53","author":"JD Szustakowski","year":"2021","unstructured":"Szustakowski JD, Balasubramanian S, Kvikstad E, Khalid S, Bronson PG, Sasson A, Wong E, Liu D, Wade Davis J, Haefliger C, et al. Advancing human genetics research and drug discovery through exome sequencing of the UK biobank. Nat Genet. 2021;53:942\u20138.","journal-title":"Nat Genet"},{"key":"1776_CR12","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1111\/j.1365-2141.2008.07281.x","volume":"142","author":"B Austen","year":"2008","unstructured":"Austen B, Barone G, Reiman A, Byrd PJ, Baker C, Starczynski J, et al. Pathogenic ATM mutations occur rarely in a subset of multiple myeloma patients. Br J Haematol. 2008;142:925\u201333.","journal-title":"Br J Haematol"},{"key":"1776_CR13","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1056\/NEJM199705153362001","volume":"336","author":"JP Struewing","year":"1997","unstructured":"Struewing JP, Hartge P, Wacholder S, Baker SM, Berlin M, McAdams M, Timmerman MM, Brody LC, Tucker MA. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med. 1997;336:1401\u20138.","journal-title":"N Engl J Med"},{"key":"1776_CR14","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1093\/jnci\/94.6.461","volume":"94","author":"H Sobol","year":"2002","unstructured":"Sobol H, Vey N, Sauvan R, Philip N, Noguchi T, Eisinger F. Re: familial multiple myeloma: a family study and review of the literature. J Natl Cancer Inst. 2002;94:461\u20132.","journal-title":"J Natl Cancer Inst"},{"key":"1776_CR15","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1007\/s11899-022-00663-7","volume":"17","author":"RJ Stubbins","year":"2022","unstructured":"Stubbins RJ, Korotev S, Godley LA. Germline CHEK2 and ATM variants in myeloid and other hematopoietic malignancies. Curr Hematol Malig Rep. 2022;17:94\u2013104.","journal-title":"Curr Hematol Malig Rep"},{"key":"1776_CR16","doi-asserted-by":"publisher","first-page":"e645","DOI":"10.1016\/j.clml.2020.10.001","volume":"21","author":"J Castiaux","year":"2021","unstructured":"Castiaux J, Vandernoot I, Dallemagne J, Bruneau M, Delaunoy M, Peyrassol X, et al. Case report of an unusual tumor in an adult with a TP53 germline mutation. Clin Lymphoma Myeloma Leuk. 2021;21:e645\u20138.","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"1776_CR17","doi-asserted-by":"publisher","first-page":"e1007111","DOI":"10.1371\/journal.pgen.1007111","volume":"14","author":"RG Waller","year":"2018","unstructured":"Waller RG, Darlington TM, Wei X, Madsen MJ, Thomas A, Curtin K, Coon H, Rajamanickam V, Musinsky J, Jayabalan D, et al. Novel pedigree analysis implicates DNA repair and chromatin remodeling in multiple myeloma risk. PLoS Genet. 2018;14:e1007111.","journal-title":"PLoS Genet"},{"key":"1776_CR18","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1038\/s41375-019-0452-6","volume":"33","author":"M Pertesi","year":"2019","unstructured":"Pertesi M, Vallee M, Wei X, Revuelta MV, Galia P, Demangel D, et al. Exome sequencing identifies germline variants in DIS3 in familial multiple myeloma. Leukemia. 2019;33:2324\u201330.","journal-title":"Leukemia"},{"key":"1776_CR19","doi-asserted-by":"publisher","first-page":"2747","DOI":"10.1158\/0008-5472.CAN-17-1900","volume":"78","author":"X Wei","year":"2018","unstructured":"Wei X, Calvo-Vidal MN, Chen S, Wu G, Revuelta MV, Sun J, et al. <article-title update=\"added\"> Germline Lysine-Specific Demethylase 1 ( LSD1\/KDM1A ) Mutations Confer Susceptibility to Multiple Myeloma. Cancer Res. 2018;78:2747\u201359.","journal-title":"Cancer Res"},{"key":"1776_CR20","doi-asserted-by":"publisher","first-page":"D980","DOI":"10.1093\/nar\/gkt1113","volume":"42","author":"MJ Landrum","year":"2014","unstructured":"Landrum MJ, Lee JM, Riley GR, Jang W, Rubinstein WS, Church DM, Maglott DR. ClinVar: public archive of relationships among sequence variation and human phenotype. Nucleic Acids Res. 2014;42:D980\u2013985.","journal-title":"Nucleic Acids Res"},{"key":"1776_CR21","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1016\/j.bbmt.2011.08.017","volume":"18","author":"CA Keever-Taylor","year":"2012","unstructured":"Keever-Taylor CA, Devine SM, Soiffer RJ, Mendizabal A, Carter S, Pasquini MC, et al. <article-title update=\"added\">Characteristics of CliniMACS\u00ae System CD34-Enriched T\u00a0Cell-Depleted Grafts in a Multicenter Trial for Acute Myeloid Leukemia-Blood and Marrow Transplant Clinical Trials Network (BMT CTN) Protocol 0303. Biol Blood Marrow Transplant. 2012;18:690\u20137.","journal-title":"Biol Blood Marrow Transplant"},{"key":"1776_CR22","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1038\/ng.806","volume":"43","author":"MA DePristo","year":"2011","unstructured":"DePristo MA, Banks E, Poplin R, Garimella KV, Maguire JR, Hartl C, Philippakis AA, del Angel G, Rivas MA, Hanna M, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data. Nat Genet. 2011;43:491\u20138.","journal-title":"Nat Genet"},{"key":"1776_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13073-015-0195-6","volume":"7","author":"M Munz","year":"2015","unstructured":"Munz M, Ruark E, Renwick A, Ramsay E, Clarke M, Mahamdallie S, et al. CSN and CAVA: variant annotation tools for rapid, robust next-generation sequencing analysis in the clinical setting. Genome Med. 2015;7:76.","journal-title":"Genome Med"},{"key":"1776_CR24","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkq603","volume":"38","author":"K Wang","year":"2010","unstructured":"Wang K, Li M, Hakonarson H. ANNOVAR: functional annotation of genetic variants from high-throughput sequencing data. Nucleic Acids Res. 2010;38:e164.","journal-title":"Nucleic Acids Res"},{"key":"1776_CR25","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.cell.2018.12.015","volume":"176","author":"K Jaganathan","year":"2019","unstructured":"Jaganathan K, Kyriazopoulou Panagiotopoulou S, McRae JF, Darbandi SF, Knowles D, Li YI, Kosmicki JA, Arbelaez J, Cui W, Schwartz GB, et al. Predicting splicing from primary sequence with deep learning. Cell. 2019;176:535\u2013e548524.","journal-title":"Cell"},{"key":"1776_CR26","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1038\/s41436-019-0463-8","volume":"21","author":"V Ravichandran","year":"2019","unstructured":"Ravichandran V, Shameer Z, Kemel Y, Walsh M, Cadoo K, Lipkin S, Mandelker D, Zhang L, Stadler Z, Robson M, Offit K, Vijai J. Toward automation of germline variant curation in clinical cancer genetics. Genet Med. 2019;21:2116\u201325.","journal-title":"Genet Med"},{"key":"1776_CR27","doi-asserted-by":"publisher","first-page":"111620","DOI":"10.1016\/j.isci.2024.111620","volume":"28","author":"F Martins Rodrigues","year":"2025","unstructured":"Martins Rodrigues F, Jasielec J, Perpich M, Kim A, Moma L, Li Y, Storrs E, Wendl MC, Jayasinghe RG, Fiala M, et al. Germline predisposition in multiple myeloma. iScience. 2025;28:111620.","journal-title":"iScience"},{"key":"1776_CR28","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1111\/bjh.14199","volume":"175","author":"LH Schinasi","year":"2016","unstructured":"Schinasi LH, Brown EE, Camp NJ, Wang SS, Hofmann JN, Chiu BC, et al. Multiple myeloma and family history of lymphohaematopoietic cancers: results from the international multiple myeloma consortium. Br J Haematol. 2016;175:87\u2013101.","journal-title":"Br J Haematol"},{"key":"1776_CR29","doi-asserted-by":"publisher","first-page":"1071","DOI":"10.1038\/s41418-022-00976-3","volume":"29","author":"KC de Andrade","year":"2022","unstructured":"de Andrade KC, Lee EE, Tookmanian EM, Kesserwan CA, Manfredi JJ, Hatton JN, Loukissas JK, Zavadil J, Zhou L, Olivier M, et al. The TP53 database: transition from the international agency for research on cancer to the US National cancer Institute. Cell Death Differ. 2022;29:1071\u20133.","journal-title":"Cell Death Differ"},{"key":"1776_CR30","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.eururo.2021.10.036","volume":"81","author":"KN Maxwell","year":"2022","unstructured":"Maxwell KN, Cheng HH, Powers J, Gulati R, Ledet EM, Morrison C, Le A, Hausler R, Stopfer J, Hyman S, et al. Inherited TP53 variants and risk of prostate cancer. Eur Urol. 2022;81:243\u201350.","journal-title":"Eur Urol"},{"key":"1776_CR31","doi-asserted-by":"publisher","first-page":"36203","DOI":"10.18632\/oncotarget.15874","volume":"8","author":"M Scales","year":"2017","unstructured":"Scales M, Chubb D, Dobbins SE, Johnson DC, Li N, Sternberg MJ, Weinhold N, Stein C, Jackson G, Davies FE, et al. Search for rare protein altering variants influencing susceptibility to multiple myeloma. Oncotarget. 2017;8:36203\u201310.","journal-title":"Oncotarget"},{"key":"1776_CR32","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41408-021-00422-6","volume":"11","author":"C Catalano","year":"2021","unstructured":"Catalano C, Paramasivam N, Blocka J, Giangiobbe S, Huhn S, Schlesner M, et al. Characterization of rare germline variants in familial multiple myeloma. Blood Cancer J. 2021;11:33.","journal-title":"Blood Cancer J"},{"key":"1776_CR33","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1200\/JCO.22.00269","volume":"41","author":"BL Lampson","year":"2023","unstructured":"Lampson BL, Gupta A, Tyekucheva S, Mashima K, Petrackova A, Wang Z, Wojciechowska N, Shaughnessy CJ, Baker PO, Fernandes SM, et al. Rare germline ATM variants influence the development of chronic lymphocytic leukemia. J Clin Oncol. 2023;41:1116\u201328.","journal-title":"J Clin Oncol"},{"key":"1776_CR34","doi-asserted-by":"publisher","first-page":"2675","DOI":"10.3390\/cells9122675","volume":"9","author":"L Stolarova","year":"2020","unstructured":"Stolarova L, Kleiblova P, Janatova M, Soukupova J, Zemankova P, Macurek L, Kleibl Z. CHEK2 germline variants in cancer predisposition: stalemate rather than checkmate. Cells. 2020;9:2675.","journal-title":"Cells"},{"key":"1776_CR35","doi-asserted-by":"publisher","first-page":"e0140819","DOI":"10.1371\/journal.pone.0140819","volume":"10","author":"O Havranek","year":"2015","unstructured":"Havranek O, Kleiblova P, Hojny J, Lhota F, Soucek P, Trneny M, et al. Association of germline CHEK2 gene variants with risk and prognosis of non-Hodgkin lymphoma. PLoS One. 2015;10:e0140819.","journal-title":"PLoS One"},{"key":"1776_CR36","doi-asserted-by":"publisher","first-page":"e532","DOI":"10.1038\/bcj.2017.15","volume":"7","author":"O Leeksma","year":"2017","unstructured":"Leeksma O, De Miranda N, Veelken H. Germline mutations predisposing to diffuse large B-cell lymphoma. Blood Cancer J. 2017;7:e532\u2013532.","journal-title":"Blood Cancer J"},{"key":"1776_CR37","first-page":"802","volume":"92","author":"J Drach","year":"1998","unstructured":"Drach J, Ackermann J, Fritz E, Kr\u00f6mer E, Schuster R, Gisslinger H, DeSantis M, Zojer N, Fiegl M, Roka S. Presence of a p53 gene deletion in patients with multiple myeloma predicts for short survival after conventional-dose chemotherapy. Blood J Am Soc Hematol. 1998;92:802\u20139.","journal-title":"Blood J Am Soc Hematol"},{"key":"1776_CR38","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.cancergencyto.2007.09.015","volume":"180","author":"K Prochazkova","year":"2008","unstructured":"Prochazkova K, Foretova L, Sedlacek Z. A rare tumor and an ethical dilemma in a family with a germline TP53 mutation. Cancer Genet Cytogenet. 2008;180:65\u20139.","journal-title":"Cancer Genet Cytogenet"},{"key":"1776_CR39","doi-asserted-by":"publisher","first-page":"1684","DOI":"10.1182\/bloodadvances.2021005482","volume":"6","author":"B Kanapuru","year":"2022","unstructured":"Kanapuru B, Fernandes LL, Fashoyin-Aje LA, Baines AC, Bhatnagar V, Ershler R, et al. Analysis of racial and ethnic disparities in multiple myeloma US FDA drug approval trials. Blood Adv. 2022;6:1684\u201391.","journal-title":"Blood Adv"},{"key":"1776_CR40","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s12920-025-02116-5","volume":"18","author":"X Chen","year":"2025","unstructured":"Chen X, Luo T, Zhang W, Wang S, Zhu M, He H, Liu J, Lu J, Qiang W, Jia Y, et al. Genomic characteristics and prognostic correlations in Chinese multiple myeloma patients. BMC Med Genomics. 2025;18:50.","journal-title":"BMC Med Genomics"},{"key":"1776_CR41","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1038\/s41467-022-35727-y","volume":"14","author":"N Light","year":"2023","unstructured":"Light N, Layeghifard M, Attery A, Subasri V, Zatzman M, Anderson ND, Hatkar R, Blay S, Chen D, Novokmet A, et al. Germline TP53 mutations undergo copy number gain years prior to tumor diagnosis. Nat Commun. 2023;14:77.","journal-title":"Nat Commun"},{"key":"1776_CR42","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41408-021-00480-w","volume":"11","author":"S Rognvaldsson","year":"2021","unstructured":"Rognvaldsson S, Love TJ, Thorsteinsdottir S, Reed ER, Oskarsson J, Petursdottir I, Sigurethardottir GA, Vietharsson B, Onundarson PT, Agnarsson BA, et al. Iceland screens, treats, or prevents multiple myeloma (iStopMM): a population-based screening study for monoclonal gammopathy of undetermined significance and randomized controlled trial of follow-up strategies. Blood Cancer J. 2021;11:94.","journal-title":"Blood Cancer J"},{"key":"1776_CR43","doi-asserted-by":"publisher","first-page":"e340","DOI":"10.1016\/S2352-3026(22)00069-2","volume":"9","author":"H El-Khoury","year":"2022","unstructured":"El-Khoury H, Lee DJ, Alberge JB, Redd R, Cea-Curry CJ, Perry J, et al. Prevalence of monoclonal gammopathies and clinical outcomes in a high-risk US population screened by mass spectrometry: a multicentre cohort study. Lancet Haematol. 2022;9:e340\u20139.","journal-title":"Lancet Haematol"},{"key":"1776_CR44","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1038\/s41591-022-02183-6","volume":"29","author":"S Thorsteinsdottir","year":"2023","unstructured":"Thorsteinsdottir S, Gislason GK, Aspelund T, Rognvaldsson S, Oskarsson J, Sigurethardottir GA, Thornorethardottir AR, Vietharsson B, Onundarson PT, Agnarsson BA, et al. Prevalence of smoldering multiple myeloma based on nationwide screening. Nat Med. 2023;29:467\u201372.","journal-title":"Nat Med"},{"key":"1776_CR45","doi-asserted-by":"publisher","DOI":"10.1101\/2024.04.19.24306082","author":"O Nadeem","year":"2024","unstructured":"Nadeem O, Aranha MP, Redd R, Timonian M, Magidson S, Lightbody ED, et al. Long-term follow-up defines the population that benefits from early interception in a high-risk smoldering multiple myeloma clinical trial using the combination of Ixazomib, Lenalidomide, and Dexamethasone. medRxiv. 2024. https:\/\/doi.org\/10.1101\/2024.04.19.24306082.","journal-title":"medRxiv"}],"container-title":["Journal of Hematology &amp; Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01776-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01776-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T17:02:10Z","timestamp":1768496530000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13045-025-01776-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,6]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["1776"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01776-1","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,6]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study is approved by the institutional review board (18\u2013339) at MSKCC. IRBs at other institutions approved sample acquisitions as described in the Supplementary Information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Dr. Douglas W Sborov declares Research support from Pfizer and advisory\/consultation with Keosys, Parexel, Pfizer, Abbvie, Janssen, Bristol Myer Squibb, GlaxoSmithKline, Legend Biotech, Opna Bio, Arcellx, Genentech, Sanofi. Dr. Usmani declares Professional Services and Activities with AstraZeneca, Bristol-Myers Squibb, GlaxoSmithKline, Janssen Biotech, Inc., Pfizer, Inc., and Regeneron Pharmaceuticals, Inc.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"10"}}